These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 17470677)

  • 21. Rebates for anti-anemia drugs draw response from FDA, CMS.
    Sipkoff M
    Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
    [No Abstract]   [Full Text] [Related]  

  • 22. [Recent advances on the use of erythropoietin in oncology].
    Spaëth D
    Bull Cancer; 2006 May; 93(5):489-93. PubMed ID: 16777627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
    Bohlius J; Schmidlin K; Brillant C; Schwarzer G; Trelle S; Seidenfeld J; Zwahlen M; Clarke M; Weingart O; Kluge S; Piper M; Rades D; Steensma DP; Djulbegovic B; Fey MF; Ray-Coquard I; Machtay M; Moebus V; Thomas G; Untch M; Schumacher M; Egger M; Engert A
    Lancet; 2009 May; 373(9674):1532-42. PubMed ID: 19410717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
    Bennett CL; Silver SM; Djulbegovic B; Samaras AT; Blau CA; Gleason KJ; Barnato SE; Elverman KM; Courtney DM; McKoy JM; Edwards BJ; Tigue CC; Raisch DW; Yarnold PR; Dorr DA; Kuzel TM; Tallman MS; Trifilio SM; West DP; Lai SY; Henke M
    JAMA; 2008 Feb; 299(8):914-24. PubMed ID: 18314434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilar epoetins.
    Macdougall IC
    Nephrol Dial Transplant; 2009 May; 24(5):1698-9; author reply 1699-700. PubMed ID: 19366858
    [No Abstract]   [Full Text] [Related]  

  • 26. Darbepoetin alfa and history of thromboembolic events.
    Ferretti G; Felici A; Cognetti F
    J Clin Oncol; 2009 Nov; 27(33):e211; author reply e212. PubMed ID: 19858373
    [No Abstract]   [Full Text] [Related]  

  • 27. New oversight put in place for physicians giving anemia drugs to patients with cancer.
    Mitka M
    JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885
    [No Abstract]   [Full Text] [Related]  

  • 28. Darbepoetin alpha coming of age.
    Pedrazzoli P; Cinieri S; Lorusso V; Gamucci T; Secondino S; Silvestris N
    Anticancer Res; 2007; 27(6C):4419-24. PubMed ID: 18214054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythropoietin-stimulating agents: new data yield new insights.
    Zitella L
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl Nurse Ed):36-8. PubMed ID: 18154208
    [No Abstract]   [Full Text] [Related]  

  • 30. Correcting anemia in heart failure: the efficacy and safety of erythropoiesis-stimulating agents.
    Lawler PR; Filion KB; Eisenberg MJ
    J Card Fail; 2010 Aug; 16(8):649-58. PubMed ID: 20670844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer.
    Marec-Berard P; Chastagner P; Kassab-Chahmi D; Casadevall N; Marchal C; Misset JL; Ray-Coquard I
    Pediatr Blood Cancer; 2009 Jul; 53(1):7-12. PubMed ID: 19229970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epoetin alfa and darbepoetin alfa go head to head.
    Steensma DP; Loprinzi CL
    J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
    Gascón P
    Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reimbursement for erythropoiesis-stimulating agents poses challenges.
    Traynor K
    Am J Health Syst Pharm; 2008 Mar; 65(5):385-6. PubMed ID: 18281727
    [No Abstract]   [Full Text] [Related]  

  • 35. The TREAT study answers a question, not the question.
    Coyne DW
    Am J Kidney Dis; 2008 Sep; 52(3):626-7; author reply 627-8. PubMed ID: 18725019
    [No Abstract]   [Full Text] [Related]  

  • 36. Erythropoiesis-stimulating agents in kidney and cardiac disease.
    Fluck R
    Br J Hosp Med (Lond); 2006 Oct; 67(10):533-7. PubMed ID: 17069130
    [No Abstract]   [Full Text] [Related]  

  • 37. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa.
    Longfield V; Gebhart B; Hayward L
    J Support Oncol; 2005; 3(6 Suppl 4):8-9. PubMed ID: 16355548
    [No Abstract]   [Full Text] [Related]  

  • 39. Managing anemia: what do we do now?
    Neumann ME
    Nephrol News Issues; 2007 May; 21(6):50, 52. PubMed ID: 17518123
    [No Abstract]   [Full Text] [Related]  

  • 40. Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
    Kelaidi C; Fenaux P
    Expert Opin Biol Ther; 2010 Apr; 10(4):605-14. PubMed ID: 20201708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.